ProCE Banner Activity

DESTINY-Lung01: Phase II Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Slideset Download
Conference Coverage
In this single-arm study in patients with previously treated HER2-mutated NSCLC, trastuzumab deruxtecan demonstrated robust antitumor activity with a safety profile consistent with previous reports.

Released: September 27, 2021

Expiration: September 26, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc